[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338518-105":59,"doc-detail-338518-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nvl-655-is-a-selective-and-brainpenetrant-inhibitor-of-diverse-alk-mutant-oncoproteins-including-lorlatinib-resistant-compound-mutations","NVL-655 Is a Selective and BrainPenetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations","","Three generations of ALK tyrosine kinase inhibitors (TKIs) exist for ALK fusion–positive non–small cell lung cancer, but current options fall short on combined resistance coverage, brain activity, and avoiding dose-limiting TRK inhibition. NVL-655 is a rationally designed TKI with >50-fold selectivity for ALK over the kinome. Preclinical studies show potent inhibition of diverse ALK fusions and resistance mutations, including improved potency versus ALKG1202R variants, with tumor regression across multiple in vivo models. Early phase I/II case studies support preliminary activity, including in brain metastases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nvl-655-is-a-selective-and-brainpenetrant-inhibitor-of-diverse-alk-mutant-oncoproteins-including-lorlatinib-resistant-compound-mutations/338518/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nvl-655-is-a-selective-and-brainpenetrant-inhibitor-of-diverse-alk-mutant-oncoproteins-including-lorlatinib-resistant-compound-mutations/338518.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What unmet needs do current ALK inhibitors have, according to the document?","Question",{"text":112,"@type":113},"Existing ALK TKIs do not adequately cover combined resistance mechanisms, achieve sufficient brain activity, or avoid clinically dose-limiting TRK inhibition.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does NVL-655 differ from approved ALK TKIs in terms of selectivity?",{"text":117,"@type":113},"NVL-655 is designed to show high selectivity for ALK over the kinome and to inhibit ALK over TRK with reported selectivity ranges spanning tens to hundreds of folds.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports NVL-655’s activity against ALK resistance mutations and CNS disease?",{"text":121,"@type":113},"Preclinical experiments show inhibition across diverse ALK fusions and single/compound resistance mutations, regression in multiple tumor models including intracranial and patient-derived xenografts, and early case studies from an ongoing phase I/II trial including patients with brain metastases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338518,1790178003,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","ReseaRch aRticle  \nNVL-655 Is a Selective and BrainPenetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant  \nCompound Mutations   \nJessica J. Lin1, Joshua C. Horan2, Anupong Tangpeerachaikul2, Aurélie Swalduz3, Augusto Valdivia4, Melissa L. Johnson5, Benjamin Besse6, D. Ross Camidge7, Toshio Fujino1, Satoshi Yoda1,  \nLinh Nguyen-Phuong1, Hayato Mizuta6, Ludovic Bigot6, Catline Nobre6, Jii Bum Lee8, Mi Ra Yu8, Scot Mente2, Yuting Sun2, Nancy E. Kohl9, James R. Porter2, Matthew D. Shair2, Viola W. Zhu2, Enriqueta Felip4, Byoung Chul Cho8, Luc Friboulet6, Aaron N. Hata1, Henry E. Pelish2, and Alexander Drilon10  \nThree generations of tyrosine kinase inhibitors (TKI) have been approved for anaplastic lymphoma kinase (ALK) fusion–positive non–small cell lung cancer.  \nHowever, none address the combined need for broad resistance coverage, brain activity, and avoidance of clinically dose-limiting TRK inhibition. NVL-655 is a rationally designed TKI with >50-fold selectivity for ALK over 96% of the kinome tested. In vitro, NVL-655 inhibits diverse ALK fusions, activating alterations, and resistance mutations, showing ≥100-fold improved potency against ALKG1202R single and compound mutations over approved ALK TKIs. In vivo, it induces regression across 12 tumor models, including intracranial and patient-derived xenografts. NVL-655 inhibits ALK over TRK with 22-fold to >874-fold selectivity. These preclinical findings are supported by three case studies from an ongoing first-in-human phase I/II trial of NVL-655 which demonstrate preliminary proof-ofconcept clinical activity in heavily pretreated patients with ALK fusion–positive non–small cell lung cancer, including in patients with brain metastases and single or compound ALK resistance mutations.  \nSIgNIfICANCe: By combining broad activity against single and compound ALK resistance mutations, brain penetrance, and selectivity, NVL-655 addresses key limitations of currently approved ALK inhibitors and has the potential to represent a distinct advancement as a fourth-generation inhibitor for patients with ALK-driven cancers.  \nintRoduction  \nThe receptor tyrosine kinase anaplastic lymphoma kinase (ALK) can be constitutively activated by aberrant gene fusion, point mutation, and partial deletion to drive human cancers (1) . Initially discovered as an oncogenic fusion in anaplastic large cell lymphoma (2), ALK fusions are present in 3% to 5% of non–small cell lung cancer (NSCLC; ref. 3), and oncogenic ALK has been detected in neuroblastomas, gliomas, inflammatory myofibroblastic tumors, and other cancers (4–8) . More than 90 fusion partners have been reported for ALK (9). EML4 accounts for 84% ofALK fusions in NSCLC (10) with at least 15 known EML4–ALK breakpoint variants, the most common of which are variant 1 (v1) and variant 3 (v3) that conjoin ALK exon 20 with EML4 exon 13 and exon 6, respectively (11) . Each fusion partner and breakpoint variant may  \n1Massachusetts General Hospital Cancer Center, Boston, Massachusetts.  \n2Nuvalent, Inc., Cambridge, Massachusetts. 3Centre Léon Bérard, Lyon, France. 4Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain. 5Sarah Cannon Research Institute, Nashville, Tennessee. 6Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France. 7University of Colorado, Anschutz Medical Campus, Aurora, Colorado. 8Yonsei University College of Medicine, Seoul, Republic of Korea. 9Kohl Consulting, Wellesley, Massachusetts. 10Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.  \nJ.J. Lin, J.C. Horan, and A. Tangpeerachaikul contributed equally to this article. Corresponding Authors: Henry E. Pelish, Nuvalent, Inc. , One Broadway, 14th Floor, Cambridge, MA 02139. E-mail: [hpelish@nuvalent. com](hpelish@nuvalent. com); and Alexander Drilon, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E 66th Street, BAIC 1203, Ne","cbCaih1OVVFhMDmL","https://ap.wps.com/l/cbCaih1OVVFhMDmL","pdf",6916311,"English","# Introduction\n# Rationale for Targeting Resistance and CNS Activity\n# NVL-655 Design and Selectivity\n## Preclinical Inhibition and Potency\n## In Vivo Efficacy Across Tumor Models\n# Clinical Evidence from First-in-Human Trial","[{\"question\":\"What unmet needs do current ALK inhibitors have, according to the document?\",\"answer\":\"Existing ALK TKIs do not adequately cover combined resistance mechanisms, achieve sufficient brain activity, or avoid clinically dose-limiting TRK inhibition.\"},{\"question\":\"How does NVL-655 differ from approved ALK TKIs in terms of selectivity?\",\"answer\":\"NVL-655 is designed to show high selectivity for ALK over the kinome and to inhibit ALK over TRK with reported selectivity ranges spanning tens to hundreds of folds.\"},{\"question\":\"What evidence supports NVL-655’s activity against ALK resistance mutations and CNS disease?\",\"answer\":\"Preclinical experiments show inhibition across diverse ALK fusions and single/compound resistance mutations, regression in multiple tumor models including intracranial and patient-derived xenografts, and early case studies from an ongoing phase I/II trial including patients with brain metastases.\"}]","NVL-655 Is a Selective and BrainPenetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations | PDF",1790024004,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b28db5d60e15b0968f978f6e12f8efe7.webp",983,1315,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1488864c7236c3633feda187f6dc710.webp",982,1314,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21081e13bc2a55f88f89543e515dcaa8.webp",981,1312,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1223f9bd3558cf65fb5697700adb2d4.webp",980,1311]